Twist Bioscience CORP Form 4 insider transactions

Emily M. Leproust, Chief Executive Officer and a Director of Twist Bioscience Corp, sold 113,318 shares of common stock on August 10, 2026 for $125.16 per share.

Robert Chess, a Director of Twist Bioscience Corp, sold 18,417 shares of common stock on August 7, 2026 for $110.89 per share.

Patrick John Finn, President and COO of Twist Bioscience Corp, sold 2,888 shares of common stock on August 3, 2026 for $85.32 per share.

Paula Green, SVP of Human Resources of Twist Bioscience Corp, sold 1,133 shares of common stock on August 3, 2026 for $85.32 per share.

Emily M. Leproust, Chief Executive Officer and a Director of Twist Bioscience Corp, sold 5,101 shares of common stock on August 3, 2026 for $85.32 per share.

Patrick John Finn, President and COO of Twist Bioscience Corp, sold 2,238 shares of common stock on July 23, 2026 for $93.89 per share.

Adam Laponis, Chief Financial Officer of Twist Bioscience Corp, sold 2,399 shares of common stock on July 9, 2026 for $94.33 per share.

Emily M. Leproust, CEO of Twist Bioscience Corp, executed a transaction under a Rule 10b5-1 trading plan, selling 18,880 shares of common stock.

Dennis Cho, Senior Vice President at Twist Bioscience, reported a sale of 14,205 shares of common stock on June 24, 2026, executed under a pre-established Rule 10b5-1 trading plan.

Paula Green, SVP of Human Resources at Twist Bioscience Corp, reported a transaction involving the sale of common stock to cover tax withholding obligations upon the vesting of Restricted Stock Units.

Dennis Cho, Senior Vice President at Twist Bioscience, sold shares to cover tax obligations related to vested Restricted Stock Units.

Emily M. Leproust, CEO of Twist Bioscience, sold 1,688 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

Twist Bioscience Corporation reports that Senior Vice President Dennis Cho sold shares to cover tax withholding obligations upon the vesting of Restricted Stock Units.

Paula Green, SVP of Human Resources at Twist Bioscience Corp, reported a transaction involving the sale of 884 shares to cover tax withholding obligations upon the vesting of Restricted Stock Units.

Emily M. Leproust, CEO and Director of Twist Bioscience Corp, reported the sale of 2,265 shares to cover tax withholding obligations upon the vesting of Restricted Stock Units.

Robert F. Werner, Chief Accounting Officer at Twist Bioscience Corp, reported transactions involving the sale of common stock.

Emily M. Leproust, CEO of Twist Bioscience Corp., has reported the sale of company shares executed under a pre-arranged 10b5-1 trading plan.

Melissa A. Starovasnik, a Director at Twist Bioscience Corp, reported a sale of 2,500 common shares on May 28, 2026, executed under a pre-established Rule 10b5-1 trading plan.

Director Melissa A. Starovasnik sold 500 shares of Twist Bioscience Corporation common stock on May 26, 2026.

Robert F. Werner, Chief Accounting Officer at Twist Bioscience Corp, reported a sale of 4,961 shares of common stock.

Twist Bioscience Corp. reports that Senior Vice President Dennis Cho sold shares to cover tax obligations related to vested Restricted Stock Units.

Emily M. Leproust, CEO and Director of Twist Bioscience Corp, reported transactions involving common stock and stock options.

Twist Bioscience Corp. reports that President and COO Patrick John Finn sold shares to cover tax withholding obligations upon the vesting of Restricted Stock Units.

Emily M. Leproust, CEO of Twist Bioscience Corp, reported transactions involving the sale of common stock and the acquisition of shares under a Rule 10b5-1 trading plan.

Twist Bioscience Corporation's Chief Financial Officer, Adam Laponis, has sold 4,000 shares of common stock as part of a pre-established Rule 10b5-1 trading plan.

Twist Bioscience Corporation CFO Adam Laponis sold 3,000 shares of common stock on April 14, 2026, pursuant to a pre-existing Rule 10b5-1 trading plan.

Twist Bioscience Corporation's Chief Financial Officer, Adam Laponis, reported a sale of 2,597 shares of common stock on April 9, 2026, to cover tax withholding obligations.

Melissa A. Starovasnik, a Director at Twist Bioscience Corp, reported a transaction involving the sale of 1,000 shares of common stock on April 1, 2026, executed under a pre-established Rule 10b5-1 trading plan.

Twist Bioscience Corp. director Robert Chess exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Twist Bioscience's President and COO, Patrick John Finn, sold 4,294 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.